Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04421027 · OUTCOME

Overall Mortality

A Study of Baricitinib (LY3009104) in Participants With COVID-19 · Source last updated 2022-07-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
event of death
Interval / dispersion
Not reported
Time frame
Day 1 to Day 28

What was measured

Number of deaths by Day 28.

Analysis population: All participants randomly assigned to study intervention.

Groups in this outcome

Placebo + SOC

Placebo administered orally QD with standard of care.

Baricitinib + SOC

4 mg baricitinib administered orally QD with standard of care.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Placebo + SOC761
Baricitinib + SOC764

Reported measurements

Source class 1
Values in event of death · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Placebo + SOC104Not reportedNot reportedNot reportedNot reported
Baricitinib + SOC65Not reportedNot reportedNot reportedNot reported

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

  1. ci Lower Limit
    0.41
    ci Num Sides
    TWO_SIDED
    ci Pct Value
    95
    ci Upper Limit
    0.78
    group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    SUPERIORITY
    p Value
    0.0018
    param Type
    Hazard Ratio (HR)
    param Value
    0.57
    statistical Method
    Log Rank
Complete source fields
analyses
  1. ci Lower Limit
    0.41
    ci Num Sides
    TWO_SIDED
    ci Pct Value
    95
    ci Upper Limit
    0.78
    group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    SUPERIORITY
    p Value
    0.0018
    param Type
    Hazard Ratio (HR)
    param Value
    0.57
    statistical Method
    Log Rank
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        104
      2. group Id
        OG001
        value
        65
denoms
  1. counts
    1. group Id
      OG000
      value
      761
    2. group Id
      OG001
      value
      764
    units
    Participants
description
Number of deaths by Day 28.
groups
  1. description
    Placebo administered orally QD with standard of care.
    id
    OG000
    title
    Placebo + SOC
  2. description
    4 mg baricitinib administered orally QD with standard of care.
    id
    OG001
    title
    Baricitinib + SOC
param Type
NUMBER
population Description
All participants randomly assigned to study intervention.
reporting Status
POSTED
time Frame
Day 1 to Day 28
title
Overall Mortality
type
SECONDARY
unit Of Measure
event of death

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice